Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature

  • Rodríguez-Otero, P.
  • Mateos, M.V.
  • Martínez-López, J.
  • Hernández, M.T.
  • Ocio, E.M.
  • Rosiñol, L.
  • Martínez, R.
  • Teruel, A.I.
  • Gutiérrez, N.C.
  • Bargay, J.
  • Bengoechea, E.
  • González, Y.
  • de Oteyza, J.P.
  • Gironella, M.
  • Nuñez-Córdoba, J.M.
  • Encinas, C.
  • Martín, J.
  • Cabrera, C.
  • Palomera, L.
  • de Arriba, F.
  • Cedena, M.T.
  • Puig, N.
  • Oriol, A.
  • Paiva, B.
  • Bladé, J.
  • Lahuerta, J.J.
  • San Miguel, J.F.
Disease control at 5 years would be a desirable endpoint for elderly multiple myeloma (MM) patients, but biomarkers predicting this are not defined. Therefore, to gain further insights in this endpoint, a population of 498 newly diagnosed transplant-ineligible patients enrolled in two Spanish trials (GEM2005MAS65 and GEM2010MAS65), has been analyzed. Among the 435 patients included in this post-hoc study, 18.6% remained alive and progression free after 5 years of treatment initiation. In these patients, overall survival (OS) rate at 10 years was 60.8% as compared with 11.8% for those progressing within the first 5 years. Hemoglobin (Hb) = 12 g/dl (OR 2.74, p = 0.001) and MGUS-like profile (OR 4.18, p = 0.005) were the two baseline variables associated with long-term disease-free survival. Upon including depth of response (and MRD), Hb = 12 g/dl (OR 2.27) and MGUS-like signature (OR 7.48) retained their predictive value along with MRD negativity (OR 5.18). This study shows that despite the use of novel agents, the probability of disease control at 5 years is still restricted to a small fraction (18.6%) of elderly MM patients. Since this endpoint is associated with higher rates of OS, this study provides important information about diagnostic and post-treatment biomarkers helpful in predicting the likelihood of disease control at 5 years.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Otros (Other)

Immunogenetic characterization of clonal plasma cells in systemic light-chain amyloidosis

  • Cuenca, I.
  • Alameda, D.
  • Sanchez-Vega, B.
  • Gomez-Sanchez, D.
  • Alignani, D.
  • Lasa, M.
  • Onecha, E.
  • Lecumberri, R.
  • Prosper, F.
  • Ocio, E.M.
  • González, M.E.
  • García de Coca, A.
  • De La Rubia, J.
  • Gironella, M.
  • Palomera, L.
  • Oriol, A.
  • Casanova, M.
  • Cabañas, V.
  • Taboada, F.
  • Pérez-Montaña, A.
  • De Arriba, F.
  • Puig, N.
  • Carreño-Tarragona, G.
  • Barrio, S.
  • Enrique de la Puerta, J.
  • Ramirez-Payer, A.
  • Krsnik, I.
  • Bargay, J.J.
  • Lahuerta, J.J.
  • Mateos, M.V.
  • San-Miguel, J.F.
  • Paiva, B.
  • Lopez, J.M.
To the Editor: Sequence-based analysis has come to play an integral role in many hematological malignancies [1], but disorders such as systemic light-chain (AL) amyloidosis remain poorly characterized due to its low incidence and small tumor size [2, 3]. Thus, greater knowledge about the immunogenetic landscape of AL amyloidosis is required since, for example, potential differences between the genomic profiles of AL amyloidosis and multiple myeloma (MM) could help identifying patients with monoclonal gammopathies at greater risk of developing AL amyloidosis and monitor presymptomatic organ damage [4, 5]. To gain further insight into the immunogenetic landscape of AL amyloidosis, we performed whole-exome sequencing (WES) on highly purified bone marrow clonal plasma cells (PCs) isolated by fluorescence activation cell sorting (FACS) based on patient-specific aberrant phenotypes. A total of 27 patients with confirmed new diagnosis of AL amyloidosis based on the presence of amyloid-related systemic syndrome, positive amyloid tissue staining with Congo red, restricted light-chain deposition by immunohistochemistry or mass spectometry, and evidence of PC clonality were investigated. Patients’ demographics and clinical characteristics are described in Supplementary Table 1. PCs were collected and processed in triplicates followed by whole genome amplification of samples with genomic DNA amounts <50 ng (Supplementary Table 2). Afterwards, library construction, exome enrichment, and sequencing were performed individually. An overall average depth of 63× and mean on-target coverage of 84% were obtained. Data were deposited in the Sequence Read Archive of the NCBI (http://www.ncbi.nlm.nih.gov/sra) under the PRJNA596656 access number...